Skip to main content
SpringerLink
Log in

Drug-Induced Tinnitus and Other Hearing Disorders

  • Review Articles
  • Pharmacoepidemiology
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Tinnitus and hearing loss, both reversible and irreversible, are associated both with acute intoxication and long term administration of a large range of drugs. The mechanism causing drug-induced ototoxicity is unclear, but may involve biochemical and consequent electrophysiological changes in the inner ear and eighth cranial nerve impulse transmission. Over 130 drugs and chemicals have been reported to be potentially ototoxic. The major classes are the aminoglycosides and other antimicrobials, anti-inflammatory agents, diuretics, antimalarial drugs, antineoplastic agents and some topically administered agents.

Prevention of drug-induced ototoxicity is generally based upon consideration and avoidance of appropriate risk factors, as well as on monitoring of renal function, serum drug concentrations, and cochlear and auditory functions before and during drug therapy. Ototoxicity, although not life-threatening, may cause considerable discomfort to patients taking ototoxic drugs, and in some cases drug discontinuation may be necessary to prevent permanent damage.

Much research has been performed to investigate the causes and mechanisms of ototoxicity, to try to prevent this complication. Despite these efforts, ototoxicity still occurs, and there is much work to be done in order to understand the mechanism of ototoxicity of different drugs and to prevent hearing loss and tinnitus in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Lien EJ, Lipsett LR, Lien LL. Structure side effect sorting of drugs: VI. Ototoxicities. J Clin Hosp Pharm 1983; 8: 15–33

    PubMed  CAS  Google Scholar 

  2. Koegel Jr L. Ototoxicity: a contemporary review of aminoglycosides, loop diuretics, acetylsalicylic acid, quinine, erythromycin, and cisplatinum. Am J Otol 1985; 6: 190–9

    PubMed  Google Scholar 

  3. Rybak LP. Drug ototoxicity. Annu Rev Pharmacol Toxicol 1986; 26: 79–99

    PubMed  CAS  Google Scholar 

  4. Boston Collaborative Drug Surveillance Program. Drug-induced deafness. JAMA 1973; 224: 515–6

    Google Scholar 

  5. Lien EJ. Side effects and drug design. New York: Marcel Dekker, 1987

    Google Scholar 

  6. Brummett RE, Griest SE, Mulkey M, et al. Specific etiologies of tinnitus. In: Shulman A, Aran JM, Tondorf J, et al., editors. Tinnitus: diagnosis and treatment. Philadelphia: Lea and Febiger, 1991: 391–8

    Google Scholar 

  7. Norris CH. Drugs affecting the inner ear. Drugs 1988; 36: 754–72

    PubMed  CAS  Google Scholar 

  8. Huang MY, Schacht J. Drug-induced ototoxicity: pathogenesis and prevention. Med Toxicol Adverse Drug Exp 1989; 4: 452–67

    PubMed  CAS  Google Scholar 

  9. Matz GJ. Clinical perspectives on ototoxic drugs. Ann Otol Rhinol Laryngol 1990; 99: 39–41

    Google Scholar 

  10. Brummett RE, Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother 1989; 33: 797–800

    PubMed  CAS  Google Scholar 

  11. Brummett RE, Morrison RB. The incidence of aminoglycoside antibiotic-induced hearing loss. Arch Otolaryngol Head Neck Surg 1990; 116: 406–10

    PubMed  CAS  Google Scholar 

  12. Lesar TS. Drug-induced ear and eye toxicity. In: Di Piro JT, Talbert RL, Hayes PE, et al., editors. Pharmacotherapy. 2nd ed., chap 82. Norwalk (CN): Appleton & Lange, 1993

    Google Scholar 

  13. De Jong TPVM, Donckerwolcke RAMG, Boemers TM. Neomycin toxicity in bladder irrigation. J Urol 1993; 150: 1199–202

    PubMed  Google Scholar 

  14. Johnson CA. Hearing loss following the application of topical neomycin. J Burn Care Rehabil 1988; 9: 162–4

    PubMed  CAS  Google Scholar 

  15. Thomas J, Marion MS, Hinojosa R. Neomycin ototoxicity. Am J Otolaryngol 1992; 13: 54–5

    PubMed  CAS  Google Scholar 

  16. Govaerts PJ, Claes J, Van De Heyning PH, et al. Aminoglycoside-induced ototoxicity. Toxicol Lett 1990; 52: 227–51

    PubMed  CAS  Google Scholar 

  17. Bergstrom L, Thompson PL. Ototoxicity. In: Northern JL, editor. Hearing disorders, 2nd ed. Boston: Little, Brown & Co., 1984: 241–54

    Google Scholar 

  18. Bendush CL. Ototoxicity: clinical toxicity and comparative information. In: Whelton A, Neu H, editors. The aminoglycosides: microbiology, clinical use and toxicology. New York: Marcel Dekker, 1982: 153–7

    Google Scholar 

  19. Griffin JP. Drug-induced ototoxicity. Br J Audiol 1988; 22: 195–210

    PubMed  CAS  Google Scholar 

  20. Takada A, Bledsoe S, Schacht J. An energy-dependent step in aminoglycoside ototoxicity: prevention of gentamycin ototoxicity during reduced endolymphatic potential. Hear Res 1985; 19: 245–51

    PubMed  CAS  Google Scholar 

  21. Dulon D, Zajic G, Aran JM, et al. Aminoglycoside antibiotics impair calcium entry but not viability and motility of cochlear outer hair cells. J Neurosci Res 1989; 24: 338–46

    PubMed  CAS  Google Scholar 

  22. Huang MY, Schact J. Formation of a cytotoxic metabolite from gentamycin by livera. Biochem Pharmacol 1990; 40: R11–4

    PubMed  CAS  Google Scholar 

  23. Crann SA, Huang MY, McLaren JD, et al. Formation of a toxic metabolite from gentamycin by a hepatic cytosolic fraction. Biochem Pharmacol 1992; 43: 1835–9

    PubMed  CAS  Google Scholar 

  24. Schact J. Biochemical basis of aminoglycoside ototoxicity. Otolaryngol Clin North Am 1993; 26: 845–56

    Google Scholar 

  25. Garetz SL, Rhee DJ, Schact J. Sulfhydryl compounds and antioxidants inhibit cytotoxicity to outer hair cells of a gentamicin metabolite in vitro. Hear Res 1994; 77: 75–80

    PubMed  CAS  Google Scholar 

  26. Garetz SL, Rhee DJ, Schact J. Attenuation of gentamicin by glutathione [abstract]. 15th Annual Meeting, Association for Research in Otolaryngology; 1993; 16: 141

    Google Scholar 

  27. Garetz SL, Altschuler RA, Schact J. Attenuation of gentamicin ototoxicity by glutathione in the guinea pig in vivo. Hear Res 1994; 77: 81–7

    PubMed  CAS  Google Scholar 

  28. Higashi K. Unique inheritance of streptomicin-induced deafness. Clin Genet 1989; 35: 433–6

    PubMed  CAS  Google Scholar 

  29. Hu DN, Qiu WQ, Wu BT, et al. Genetic aspects of antibioticinduced deafness: mitochondrial inheritance. J Med Genet 1991; 28: 79–83

    PubMed  CAS  Google Scholar 

  30. Prezant TR, Agapian JV, Bohlman MC, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nature Genet 1993; 4: 289–94

    PubMed  CAS  Google Scholar 

  31. Hutchin T, Haworth I, Higashi K, et al. A molecular basis for human hypersensitivity to aminoglycoside antibiotics. Nucleic Acids Res 1993; 21: 4174–9

    PubMed  CAS  Google Scholar 

  32. Cortopassi G, Hutchin T. A molecular and cellular hypothesis for aminoglycoside-induced deafness. Hear Res 1994; 78: 27–30

    PubMed  CAS  Google Scholar 

  33. Black FO, Pesznecker SC. Vestibular ototoxicity: clinical considerations. Otolaryngol Clin North Am 1993; 26: 713–36

    PubMed  CAS  Google Scholar 

  34. Moore RD, Smith CR, Lietman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 1984; 149: 23–30

    PubMed  CAS  Google Scholar 

  35. Haydon RC, Thelin JW, Davis WE. Erythromycin ototoxicity: analysis and conclusions based on 22 case reports. Otolaryngol Head Neck Surg 1984; 92: 678–84

    PubMed  CAS  Google Scholar 

  36. Schweitzer VG, Olson NR. Ototoxic effect of erythromycin therapy. Arch Otolaryngol 1984; 110: 258–60

    PubMed  CAS  Google Scholar 

  37. Dantzenberg B, Piperno D, Diot P, et al. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients with AIDS: Clarithromycin Study Group of France. Chest 1995; 107: 1035–40

    Google Scholar 

  38. Cramer R. Erythromycin ototoxicity. Drug Intell Clin Pharm 1986; 20: 764–5

    Google Scholar 

  39. Swanson DJ, Sung RJ, Fine MJ, et al. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med 1992; 92: 61–8

    PubMed  CAS  Google Scholar 

  40. Brummett RE. Ototoxic liability of erythromycin and analogues. Otolaryngol Clin North Am 1993; 26: 811–9

    PubMed  CAS  Google Scholar 

  41. Sacristán JA, Soto J. Erythromycin ototoxicity: methodology and conclusions [letter]. Am J Med 1993; 94: 227–8

    PubMed  Google Scholar 

  42. Kanfer A, Stamatakis G, Torlotin C, et al. Changes in erythromycin pharmacokinetics induced by renal failure. Clin Nephrol 1987; 29: 147–50

    Google Scholar 

  43. Brittain DC. Erythromycin. Med Clin North Am 1987; 71: 1147–54

    PubMed  CAS  Google Scholar 

  44. Swanson DJ, Derry CL Fine MJ, et al. Erythromycin pharmacokinetics associated with ototoxic effects in patients. Pharmacotherapy 1990; 10: 232–6

    Google Scholar 

  45. Moral A, Navasa M, Rimola A, et al. Erythromycin ototoxicity in liver transplant patients. Transpl Int 1994; 7: 62–4

    PubMed  CAS  Google Scholar 

  46. Brummett RE, Fox KE. Vancomycin- and erythromycininduced hearing loss in humans. Antimicrob Agents Chemother 1989; 33: 791–6

    PubMed  CAS  Google Scholar 

  47. Brummett RE, Morrison R, Matthews J. Possible site of action of erythromycin ototoxicity in the human [abstract]. 11th Annual Meeting, Association for Research in Otolaryngology; 1989

  48. Wallace MR, Miller LK, Nguyen M-T. Ototoxicity with azithromycin. Lancet 1994; 343: 241–3

    PubMed  CAS  Google Scholar 

  49. Farber BF, Moellering RC. Retrospective study of the preparations of vancomycin from 1974–1981. Antimicrob Agents Chemother 1987; 23: 138–41

    Google Scholar 

  50. Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity: a review. Med Toxicol Adverse Drug Exp 1988; 3: 376–86

    PubMed  CAS  Google Scholar 

  51. Hermans PE, Wilheim MR. Vancomycin. Mayo Clin Proc 1987; 62: 901–5

    PubMed  CAS  Google Scholar 

  52. Brummett RE. Ototoxicity of vancomycin and analogues. Otolaryngol Clin North Am 1993; 26: 821–8

    PubMed  CAS  Google Scholar 

  53. Lutz H, Lenarz T, Weidauer H, et al. Ototoxicity of vancomycin: an experimental study in guinea pigs. ORL J Otorhinolaryngol Relat Spec 1991; 53: 273–8

    PubMed  CAS  Google Scholar 

  54. Goodey RJ. Drugs in the treatment of tinnitus. In: Kitaha M, editor. Tinnitus: pathophysiology and management. Tokyo: Igaku-Shoin, 1988: 64–73

    Google Scholar 

  55. Shulman A. Medical methods, drug therapy, and tinnitus control strategies. In: Shulman A, Aran JM, Tondorf J, et al., editors. Tinnitus: diagnosis and treatment. Philadelphia: Lea and Febiger, 1991: 453–89

    Google Scholar 

  56. Drew TM, Altman R, Black K, et al. Minocycline for prophylaxis of infection in Neisseria meningitidis: high rate of side effects in recipients. J Infect Dis 1976; 133: 194–8

    PubMed  CAS  Google Scholar 

  57. Gump GW, Ashikaga T, Fink T, et al. Side effects of minocycline: different dosage regimens. Antimicrob Agents Chemother 1977; 12: 642–6

    PubMed  CAS  Google Scholar 

  58. Giles CL, Soble AR. Intracranial hypertension and tetracycline therapy. Am J Ophthalmol 1971; 72: 981–2

    PubMed  CAS  Google Scholar 

  59. Ohlrich GD, Ohlrich JG. Papilloedema in an adolescent due to tetracycline. Med J Aust 1977; 1: 334–5

    PubMed  CAS  Google Scholar 

  60. Walters BNJ, Gubbay SS. Tetracycline and benign intracranial hypertension: report of five cases. BMJ 1981; 282: 19–20

    PubMed  CAS  Google Scholar 

  61. Davis DM. Drug-induced deafness. Adverse Drug React Bull 1978; 69: 244–77

    Google Scholar 

  62. Drucker T. Drugs that can cause tinnitus. ATA Newslett 1979; 4: 3–5

    Google Scholar 

  63. Brummett RE. Drug-induced ototoxicity. Drugs 1980; 19: 412–28

    PubMed  CAS  Google Scholar 

  64. Miller JJ. Handbook of ototoxicity. Boca Raton (FL): CRC Press, 1980

    Google Scholar 

  65. Dukes MNG, Aronson JK, editors. Meyler’s side effects of drugs. 11th ed. Amsterdam: Elsevier, 1990 651–9

    Google Scholar 

  66. Miwa T, Tsukamura M, Kawase Y, et al. Adverse reactions of enviomycin during treatment for pulmonary tuberculosis. Tuberculosis 1980; 55: 201–6

    PubMed  CAS  Google Scholar 

  67. Gorman SE, Dela Cruz F, Paloucek F. Ketoconazole and zidovudine overdose: case report and review. Vet Hum Toxicol 1992; 34: 332

    Google Scholar 

  68. Costa I, Castanet J, Lacour JP, et al. Vertigo and hypokalaemia: two rare adverse effects of itraconazole. Therapie 1994; 49: 149

    PubMed  CAS  Google Scholar 

  69. Davanipour Z, Stewart CE, McGann DG. Hepatitis B vaccination and asymmetric tinnitus and hearing loss [abstract]. Clin Res 1994; 42: 341A

    Google Scholar 

  70. Stewart BJA, Umesh Prabhu P. Reports of sensorineural deafness after measles, mumps, and rubella immunisation. Arch Dis Child 1993; 69: 153–5

    PubMed  CAS  Google Scholar 

  71. Hulbert TV, Larsen RA, Davis CL, et al. Bilateral hearing loss after measles and rubella vaccination in an adult [letter]. N EnglJ Med 1991; 325: 134

    CAS  Google Scholar 

  72. Kanda Y, Shigeno K, Kinoshita N, et al. Sudden hearing loss associated with interferon. Lancet 1994; 343: 1134–5

    PubMed  CAS  Google Scholar 

  73. Walker EM, Fazekas-May MA, Bowen WR. Nephrotoxic and ototoxic agents. Clin Lab Med 1990; 10: 323–54

    PubMed  CAS  Google Scholar 

  74. Day RO, Graham GG, Bieri D, et al. Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers. Br J Clin Pharmacol 1989; 28: 695–702

    PubMed  CAS  Google Scholar 

  75. Brien J. Ototoxicity associated with salicylates. Drug Saf 1993; 9: 143–8

    PubMed  CAS  Google Scholar 

  76. Temple AR. Acute and chronic effects of aspirin toxicity and their treatment. Arch Intern Med 1981; 141: 364–9

    PubMed  CAS  Google Scholar 

  77. Miller RR, Jick H. Acute toxicity of aspirin in hospitalized medical patients. Am J Med Sci 1977; 274: 271–9

    PubMed  CAS  Google Scholar 

  78. Hawkins J, Johnson L, Preston R. Cochlear microvasculature in normal and damaged ear. Laryngoscope 1971; 82: 1091–4

    Google Scholar 

  79. Malotte M, Jung TTK, Miller SK, et al. Effect of nonsteroidal anti-inflammatory drugs on cochlear blood flow. Otolaryngol Head Neck Surg 1990; 103: 187–9

    Google Scholar 

  80. Jung T, Juhn S. Prostaglandins in the perilymph. 7th Midwinter Research Meeting, Association for Research in Otolaryngology; 1984: 107–8

    Google Scholar 

  81. Kawata R, Urade Y, Tachibana M, et al. Prostaglandin synthesis by the cochlea. Prostaglandins 1988; 35: 173–84

    PubMed  CAS  Google Scholar 

  82. Cazals Y, Li X, Aurousseau C, et al. Acute effects of noradrenaline-related vasoactive agents on the ototoxicity of aspirin. Hear Res 1988; 36: 89–96

    PubMed  CAS  Google Scholar 

  83. Jung T, Miller S, Mowery G, et al. Effect of leukotriene inhibitor (L-663536) on metabolites in salicylate ototoxicity. 14th Midwinter Research Meeting, Association for Research in Otolaryngology; 1991: 73–4

    Google Scholar 

  84. Jung T, Park Y, Miller S, et al. Effects of exogenous arachidonic acid metabolites applied on round window membrane on hearing, and their levels in the perilymph. Acta Otolaryngol 1992; Suppl. 493: 171–6

    CAS  Google Scholar 

  85. Ishii T, Bernstein JM, Balogh Jr K. Distribution of tritiumlabelled salicylate in the cochlea: an autoradiographical study. Ann Otol Rhinol Laryngol 1967; 76: 368–76

    PubMed  CAS  Google Scholar 

  86. Silverstein H, Bernstein JM, Davis DG. Salicylate toxicity: a biochemical and electrophysiological study. Ann Otol Rhinol Laryngol 1967; 76: 118–28

    PubMed  CAS  Google Scholar 

  87. Krzanowski Jr JJ, Matschinsky FM. A phosphocreatine gradient opposite to that of glycogen in the organ of Corti and the effect of salicylate on adenosine triphosphate and P-creatine in cochlear structures. J Histochem Cytochem 1971; 19: 321–4

    PubMed  CAS  Google Scholar 

  88. McCabe PA, Dey DL. The effect of aspirin upon auditory sensitivity. Ann Otol Rhinol Laryngol 1965; 74: 312–25

    PubMed  CAS  Google Scholar 

  89. McFadden D. Tinnitus: facts, theories and treatments. Washington, DC: National Academy Press, 1982

    Google Scholar 

  90. Lindgren F, Axellson A. Temporary threshold shift induced by noise exposure and moderate salicylate intake. Scand Audiol 1987; 16: 41–4

    Google Scholar 

  91. Günther T, Rebentisch E, Vormann J. Enhanced ototoxicity of salicylate by magnesium deficiency. Magnes Bull 1989; 11: 15–8

    Google Scholar 

  92. Günther T, Rebentisch E, Vormann J. Protection against salicylate ototoxicity by zinc. J Trace Elem Electrolytes Health Dis 1989; 3: 51–3

    PubMed  Google Scholar 

  93. Fratianni T, Jung TTK, Miller SK, et al. Effect of adrenergic blockers on sodium salicylate-induced ototoxicity. Otolaryngol Head Neck Surg 1990; 103: 233–6

    Google Scholar 

  94. Pinals RS, Frank S. Relative efficiency of indomethacin and acetylsalicylic acid in rheumatoid arthritis. N Engl J Med 1967; 276: 512–4

    PubMed  CAS  Google Scholar 

  95. Lynch S, Brogden RN. Etodolac: a preliminary review of its pharmacodynamic activity and therapeutic use. Drugs 1986; 31: 288–300

    PubMed  CAS  Google Scholar 

  96. Wasner C, Britton MC, Kraines G, et al. Nonsteroidal antiinflammatory agents in rheumatoid arthritis and ankylosing spondylitis. JAMA 1981; 246: 2168–72

    PubMed  CAS  Google Scholar 

  97. Chapman P. Naproxen and sudden hearing loss. J Laryngol Otol 1982; 96: 163–6

    PubMed  CAS  Google Scholar 

  98. Morris DL, Fletcher A. Hyperacusis after treatment with mefenamic acid. BMJ 1986; 293: 823

    Google Scholar 

  99. Clissold SP, Beresfold R. Proquazone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficiency in rheumatic diseases and pain states. Drugs 1987; 33: 478–502

    PubMed  CAS  Google Scholar 

  100. Gallagher KL, Jones JR. Furosemide-induced ototoxicity. Ann Intern Med 1979; 91: 744–5

    PubMed  CAS  Google Scholar 

  101. Rybak LP. Ototoxicity of loop diuretics. Otolaryngol Clin North Am 1993; 26: 829–44

    PubMed  CAS  Google Scholar 

  102. Hommerich CP. Ototoxicity of loop diuretics: morphological and electrophysiological examinations in animal experiments. Adv Otorhinolaryngol 1990; 44: 92–164

    PubMed  CAS  Google Scholar 

  103. Wells TG. The pharmacology and therapeutics of diuretics in the pediatric patient. Pediatr Clin North Am 1990; 37: 463–504

    PubMed  CAS  Google Scholar 

  104. Wigand ME, Heidland A. Ototoxic side effects of high doses of furosemide in patients with uremia. Postgrad Med J 1971; 47 Suppl.: 54–6

    PubMed  Google Scholar 

  105. Kshirsager N, Dohanukar SA, Shah BP. Furosemide pharmacokinetics and its relevance to ototoxicity. J Postgrad Med 1978; 24: 20–3

    Google Scholar 

  106. Ng PSY, Conley CE, Ing TS. Deafness after ethacrynic acid. Lancet 1969; i: 673–4

    Google Scholar 

  107. Melichar I, Syka J. The effects of ethacrynic acid upon the potassium concentration in guinea pig cochlear fluids. Hear Res 1978; 1: 35–41

    PubMed  CAS  Google Scholar 

  108. Koch T, Gloddek B. Inhibition of adenylate cyclase-coupled G protein complex by ototoxic diuretics and cis-platinum in the inner ear of guinea pigs. Eur Arch Otorhinolaryngol 1991; 248: 459–64

    PubMed  CAS  Google Scholar 

  109. Rybak LP, Whitwoch C, Scott V. Organic acids do not alter the cochlear effects of ethacrynic acid. Hear Res 1990; 46: 95–100

    PubMed  CAS  Google Scholar 

  110. Tuzel IH. Comparison of adverse reactions to bumetanide and furosemide. J Clin Pharmacol 1981; 21: 615–9

    PubMed  CAS  Google Scholar 

  111. Keefe PE. Ototoxicity from oral furosemide. Drug Intell Clin Pharm 1978; 12: 428–30

    Google Scholar 

  112. Heidland A, Wigand ME. Hearing loss induced by the use of high doses of furosemide in the treatment of uremia [in German]. Klin Wochenschr 1970; 48: 1052–6

    PubMed  CAS  Google Scholar 

  113. Rybak LP, Morizono T. Effect of furosemide upon endolymph potassium concentration. Hear Res 1982; 7: 223–31

    PubMed  CAS  Google Scholar 

  114. Dunn CJ, Fitton A, Brogden RN. Torasemide: an update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49: 121–42

    PubMed  CAS  Google Scholar 

  115. Toone EC. Ototoxicity of chloroquine. Arthritis Rheum 1965; 8: 475–6

    Google Scholar 

  116. Dwivedi GS, Mehra YN. Ototoxicity of chloroquine phosphate. J Laryngol Otol 1978; 92: 701–3

    PubMed  CAS  Google Scholar 

  117. Miller JJ. CRC handbook of ototoxicity. Boca Raton (FL): CRC Press, 1985

    Google Scholar 

  118. Schonwald S, Shannon M. Unsuspected quinine intoxication presenting as acute deafness and mutism. Am J Emerg Med 1991; 9: 318–20

    PubMed  CAS  Google Scholar 

  119. Manku MS, Horrobin DF. Chloroquine, quinine, procaine, quinidine, tricyclic anti-depressants, and methylxanthines as prostaglandin agonists and antagonists. Lancet 1976; ii: 1115–7

    Google Scholar 

  120. Smith DI, Lawrence M, Hawkins JE. Effects of noise and quinine on the vessels of the stria vascularis: an image analysis study. Am J Otolaryngol 1985; 6: 280–9

    PubMed  CAS  Google Scholar 

  121. Short SO, Kaplan JN. Changes in cochlear blood flow and hearing with acute quinine toxicity. Otolaryngol Head Neck Surg 1983; 91: 100–3

    Google Scholar 

  122. Moss RA. Drug-induced immune thrombocytopenia. Am J Hematol 1980; 9: 439–46

    PubMed  CAS  Google Scholar 

  123. Jung TT, Rhee CK, Lee CS, et al. Ototoxicity of salicylate, nonsteroidal anti-inflammatory drugs and quinine. Otolaryngol Clin North Am 1993; 26: 791–810

    PubMed  CAS  Google Scholar 

  124. Puel J-L, Bobbin RP, Fallon M. Salicylate, mefenamate, meclofenamate, and quinine on cochlear potentials. Otolaryngol Head Neck Surg 1990; 102: 66–73

    PubMed  CAS  Google Scholar 

  125. Dukes MNG, Aronson JK, editors. Meyler’s side effects of drugs. 11th ed. Amsterdam: Elsevier, 1990 581–602

    Google Scholar 

  126. Moroso MJ, Blair R. A review of cisplatin ototoxicity. J Otolaryngol 1983; 12: 365–9

    PubMed  CAS  Google Scholar 

  127. Schweitzer VG. Ototoxicity of chemotherapeutic agents. Otolaryngol Clin North Am 1993; 26: 759–89

    PubMed  CAS  Google Scholar 

  128. Pasic TR, Dobie RA. cis-Platinum ototoxicity in children. Laryngoscope 1991; 101: 985–91

    PubMed  CAS  Google Scholar 

  129. Vermorken J. Ototoxicity of cis-diamminedichloroplatinum: influence of dose schedule and mode of administration. Eur J Cancer Clin Oncol 1983; 19: 53–8

    PubMed  CAS  Google Scholar 

  130. Schaeffer SD, Wright FG, Post JD. Cisplatin vestibular toxicity. Cancer 1981; 47: 857–9

    Google Scholar 

  131. McAlpine D. The ototoxic mechanism of cisplatin. Hear Res 1990; 47: 191–204

    PubMed  CAS  Google Scholar 

  132. Myers S. The ‘platinum effect’ of cis-platinum-induced hearing loss. Otolaryngol Head Neck Surg 1991; 104: 122–7

    PubMed  CAS  Google Scholar 

  133. Blakley BW, Gupta AK, Myers SF, et al. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg 1994; 120: 541–6

    PubMed  CAS  Google Scholar 

  134. Plinkert PK, Krober S. Early detection of cisplatin-induced ototoxicity using evoked otoacoustic emissions [in German]. Laryngorhinootologie 1991; 70: 457–62

    PubMed  CAS  Google Scholar 

  135. Schweitzer VG, Dolan DF, Davidson T. Amelioration of cisplatin-induced ototoxicity by fosfomycin. Laryngoscope 1986; 96: 948–58

    PubMed  CAS  Google Scholar 

  136. Meyer WH, Ayers D, McHaney VA. Ifosfamide and exacerbation of cisplatin-induced hearing loss. Lancet 1993; 341: 754–5

    PubMed  CAS  Google Scholar 

  137. Golden L, Ahlgren JD, Kattah J. Cochleovestibular toxicity related to dichloromethotrexate. Cancer Invest 1989; 7: 345–8

    PubMed  CAS  Google Scholar 

  138. Lugassay G. Sensorineural hearing loss associated with vincristine. Blut 1990; 61: 320–1

    Google Scholar 

  139. Yousif H, Richardson SGN, Saunders WA. Partially reversible nerve deafness due to vincristine. Postgrad Med J 1990; 66: 688–9

    PubMed  CAS  Google Scholar 

  140. Dukes MNG, Aronson JK, editors. Meyler’s side effects of drugs. 11th ed. Amsterdam: Elsevier, 1990 928–60

    Google Scholar 

  141. Rohn GN, Meyerhoff WL, Wright GG. Ototoxicity of topical agents. Otolaryngol Clin North Am 1993; 26: 747–58

    PubMed  CAS  Google Scholar 

  142. Podoshin L, Fradis M, Ben-David J. Ototoxicity of ear drops in patients suffering from chronic otitis media. J Laryngol Otol 1989; 103: 46–50

    PubMed  CAS  Google Scholar 

  143. Bicknell PG. Sensorineural deafness following myringoplasty operations. J Laryngol Otol 1971; 85: 957–61

    PubMed  CAS  Google Scholar 

  144. Roland PS. Clinical ototoxicity of topical antibiotic drops. Otolaryngol Head Neck Surg 1994; 110: 598–602

    PubMed  CAS  Google Scholar 

  145. Spandow O. Are glucocorticoids in ear drops ototoxic? Acta Otolaryngol 1992; Suppl. 493: 89–91

    CAS  Google Scholar 

  146. Ballantyne JC. Ototoxicity. J Laryngol Otol 1983; 8 Suppl.: 9–12

    CAS  Google Scholar 

  147. Gendeh BS, Said H, Gibb AG, et al. Gentamicin administration via peritoneal dialysis fluid: the risk of ototoxicity. J Laryngol Otol 1991; 105: 999–1001

    PubMed  CAS  Google Scholar 

  148. De Jong RH. Systemic toxicity of local anaesthetics. Anaesthesist 1980; 29: 49–51

    PubMed  Google Scholar 

  149. Linder S, Borgeat A, Biollaz J. Meniere-like syndrome following epidural morphine analgesia. Anesthesiology 1989; 71: 782–3

    PubMed  CAS  Google Scholar 

  150. Epstein M, Jardine RM, Obel IWP. Flecainide acetate in the treatment of resistant supraventricular arrhythmia. S Afr Med J 1988; 74: 559–62

    PubMed  CAS  Google Scholar 

  151. Narváez M, Figueras A, Capellà D, et al. Tinnitus with calciumchannel blockers [letter]. Lancet 1994; 343: 1229–30

    PubMed  Google Scholar 

  152. Armon C, Brown E, Carwile S, et al. Valproate-induced sensorineural hearing impairment. Epilepsia 1990; 31: 601–3

    Google Scholar 

  153. Armon C, Brown E, Carwile S, et al. Sensorineural hearing loss: a reversible effect of valproic acid. Neurology 1990; 40: 1896–8

    PubMed  CAS  Google Scholar 

  154. Armon C, Paul RG, Miller P, et al. Valproate-induced hearing impairment: active ascertainment in an epilepsy clinic population, and results of therapeutic intervention. Epilepsia 1991; 32 Suppl. 3: 17–8

    Google Scholar 

  155. Swedish Adverse Drug Reactions Advisory Committee. Enalapril: hearing loss. Bulletin from SADRAC 1990; 1 (57)

  156. Kimbel KH. Suspension of licence for intravenous omeprazole in Germany. Lancet 1994; 344: 756–9

    PubMed  CAS  Google Scholar 

  157. Arinsoy T, Akpolat T, Ataman M, et al. Sudden hearing loss in a cyclosporin-treated renal transplantation patient. Nephron 1993; 63: 116–7

    PubMed  CAS  Google Scholar 

  158. Ramsay BC. Complete deafness after abuse of co-proxamol. Lancet 1991; 338: 446–7

    PubMed  CAS  Google Scholar 

  159. Feder R. Tinnitus associated with amitriptyline. J Clin Psychiatry 1990; 51: 85–6

    PubMed  CAS  Google Scholar 

  160. Malone Jr DA. Tone discrimination secondary to amitriptyline. J Clin Psychopharmacol 1991; 11: 221–2

    PubMed  Google Scholar 

  161. Marais J. Cochleotoxicity due to mianserin hydrochloride. J Laryngol Otol 1991; 105: 475–6

    PubMed  CAS  Google Scholar 

  162. Mattes JA. MAOIs and Meniere’s syndrome. Am J Psychiatry 1990; 147: 534–7

    PubMed  CAS  Google Scholar 

  163. Cunningham M, Cunningham K, Lydiard RB. Eye tics and subjective hearing impairment during fluoxetine therapy. Am J Psychiatry 1990; 147: 947–8

    PubMed  CAS  Google Scholar 

  164. Busto U, Fornazzari L, Naranjo CA. Protracted tinnitus after discontinuation of long-term therapeutic use of benzodiazepines. J Clin Psychopharmacol 1988; 8: 359–62

    PubMed  CAS  Google Scholar 

  165. Reynold JEF, editor. Martindale: the extra pharmacopeia. 30th ed. London: Pharmaceutical Press, 1933 807

    Google Scholar 

  166. Dukes MNG, Aronson JK, editors. Meyler’s side effects of drugs. 11th ed. Amsterdam: Elsevier, 1990 437–60

    Google Scholar 

  167. Gallant T, Boyden MH, Gallant M, et al. Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. Am J Med 1987; 83: 1085–90

    PubMed  CAS  Google Scholar 

  168. Cases A, Kelly J, Sabater F, et al. Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine. Nephron 1990; 56: 19–23

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Clinical Pharmacology, Bnai Zion Medical Center, Haifa, Israel

    Hannah Seligmann

  2. Department of Otolaryngology — Head and Neck Surgery, Bnai Zion Medical Center, POB 4940, 31048, Haifa, Israel

    Ludwig Podoshin, Jacob Ben-David, Milo Fradis & Moshe Goldsher

  3. The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

    Ludwig Podoshin, Jacob Ben-David & Milo Fradis

Authors
  1. Hannah Seligmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ludwig Podoshin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jacob Ben-David
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Milo Fradis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Moshe Goldsher
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seligmann, H., Podoshin, L., Ben-David, J. et al. Drug-Induced Tinnitus and Other Hearing Disorders. Drug-Safety 14, 198–212 (1996). https://doi.org/10.2165/00002018-199614030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199614030-00006

Keywords

Search

Navigation